Drug Profile
Research programme: lung disorder therapies - RespiVert
Alternative Names: RV-1088Latest Information Update: 16 Jul 2016
Price :
$50
*
At a glance
- Originator RespiVert
- Class Small molecules
- Mechanism of Action Phosphatidylinositol 3 kinase delta inhibitors; Phosphatidylinositol 3 kinase gamma inhibitors; Phosphotransferase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Asthma; Chronic obstructive pulmonary disease; Cystic fibrosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Asthma in United Kingdom (Inhalation)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Chronic-obstructive-pulmonary-disease in United Kingdom (Inhalation)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Cystic-fibrosis in United Kingdom (Inhalation)